Log in to your Inderes Free account to see all free content on this page.
Egetis Therapeutics
4.67 SEK -6.32%Be the first to follow this company
Egetis Therapeutics is a drug development company, focused on projects in late clinical development in the field of orphan drugs for the treatment of serious and rare diseases with significant medical needs. Examples of the company's drug candidates are Emcitate, which is developed for patients with MCT8 deficiency, and Aladote, which is developed to reduce acute liver damage.
Revenue
57.6M
EBIT %
-563.89 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
EGTX
Daily low / high price
4.655 / 5.05
SEK
Market cap
1.37B SEK
Turnover
4.31M SEK
Volume
902K
Latest videos
Financial calendar
Interim report
22.08.2024
Interim report
08.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Frazier Life Sciences | 13.2 % | 13.2 % |
Peder Walberg | 11.5 % | 11.5 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Egetis announces topline results of the Phase 2 Triac Trial II with Emcitate® (tiratricol) for MCT8 deficiency
Egetis awarded Promising Innovative Medicine designation in the UK for Emcitate® (tiratricol) for treatment of MCT8 deficiency
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio